Option chain shows key data for Zealand Pharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Zealand Pharma.

Zealand Pharma (OTC:ZLDPF) Stock, Option Chain

Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Siegen,,North,Rhine,Westphalia,,,Germany,-,10,11,2023:

Analyst Color

Biotech

Large Cap

News

Health Care

Analyst Ratings

Movers

General

AMGN

RHHBY

VKTX

ZLDPF

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly&#39;s dominance while addressing scalability and pricing concerns.

Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names

Earnings

Mid Cap

Markets

Trading Ideas

While &#34;the trend is your friend&#34; when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn&#39;t easy.

Recent Price Trend in Zealand Pharma AS is Your Friend, Here&#39;s Why

globe chart shutter

Specialty ETFs

Small Cap Analysis

Technicals

Small Cap

Global

ETFs

ADDHY

DITHF

MAKSF

SCZ, an ETF tracking small-caps outside of NA, hits 52-wk high at $65.60. Strong performance of top holdings and bullish trends point to continued success.

International Small-Cap ETF Reaches 52-Week High, Leaving Investors Wondering What&#39;s Next

ZEALAND PHARMA A/S ORD by Zealand Pharma A/S

Zealand Pharma AS

Danske Bank upgraded Zealand Pharma (ZLDPF) to Hold from Sell with an DKK 825 price target Published first on TheFly – the ultimate source for real...

Zealand Pharma upgraded to Hold from Sell at Danske Bank

Zealand Pharma (ZLDPF) announced that the first participant has been enrolled in ZUPREME-1, a global Phase 2b trial in people with obesity or overw...

Zealand Pharma announces first participant enrolled in ZUPREME-1

Berenberg Bank analyst Laura Hindley maintained a Buy rating on Zealand Pharma (ZLDPF – Research Report) yesterday and set a price target of DKK1,0...

Berenberg Bank Sticks to Their Buy Rating for Zealand Pharma (ZLDPF)

Altimmune 2025: Redefining Obesity And MASH Treatment

Zealand Pharma A/S 2024 Q3 - Results - Earnings Call Presentation

Zealand Pharma And Eli Lilly: Strategic Focus On Weight Management And Future Outlook

Zealand Pharma (ZLDPF) announced that the U.S. Food and Drug Administration has issued a Complete Response Letter for the company's New Drug Applic...

Zealand Pharma says FDA issues CRL for glepaglutide NDA

FDA rejects Zealand Pharma's drug for short bowel syndrome

Shares of Ironwood Pharmaceuticals (IRWD) are up $1.17, or 30%, to $5.06 after Zealand Pharma (ZLDPF) announced that the Food and Drug Administrati...

Ironwood jumps after FDA rejects Zealand short bowel syndrome drug application

Jefferies analyst Lucy Codrington maintained a Buy rating on Zealand Pharma (ZLDPF – Research Report) today and set a price target of DKK1,100.00. ...

Comments

Zealand Pharma

Zealand Pharma (ZLDPF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga